Childhood and adolescent cancers

GSK213406

A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of;Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours

Open at Paris since : 01/04/2021
Target : Child
Phase : Phase I

Trial description

This study will evaluate the combination of a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, niraparib, with the programmed cell death protein 1 (PD-1) inhibitor, dostarlimab in the pediatric population. This study will be conducted to determine the recommended Phase 2 dose (RP2D) and evaluate the pharmacokinetics (PK), safety, and efficacy of niraparib in combination with dostarlimab in pediatric participants with recurrent or refractory solid tumors.

Url of the trial

Main investigator

FRANCOIS DOZ

Professeur - Médecin

Contact